К содержанию
РецензированоEN2016

THE MODERN PHARMACOLOGICAL AND THERAPEUTIC APPROACHES TO ANKYLOSING SPONDYLITIS: A REVIEW OF CURRENT GUIDELINES AND TREATMENT STRATEGIES

МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ · АКАДЕМИЧЕСКИХ НАУК · Abdujabborov Jamshidbek · Omonov Jamshid · Tursunboev Ulugbek · Kushboeva Shabnam · Abdurakhmanova Sayyora

Международная конференция академических наук · 6 · 235-238 · 2016

Аннотация

Ankylosing spondylitis (AS) is a chronic autoimmune disease primarily affecting the spine and lumbosacral joints, characterized by inflammation that can lead to significant disability. Associated with the human leukocyte antigen B27 (HLA-B27), AS affects 0.1-1.5% of the global population, with a notably higher prevalence in men, typically beginning before the age of 40. The disease has a profound impact on the quality of life, often leading to early disability among young adults. The chronicity of the disease, combined with its potential for severe functional impairment, highlights the importance of timely and effective treatment.

Доказательный фрагмент

«Ankylosing spondylitis (AS) is a chronic autoimmune disease primarily affecting the spine and lumbosacral joints, characterized by inflammation that can lead to significant disability.»

Образец извлечения

Демо-превью

Ankylosing spondylitis (AS) is a chronic autoimmune disease primarily affecting the spine and lumbosacral joints, characterized by inflammation that can lead to significant disability. Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.

Цитирований
0
Тип
Журнал
Страна
Узбекистан
Ключевые слова
disease, disability, ankylosing, spondylitis, chronic, autoimmune, primarily
Открыть DOI
Спросить CiteX об этой работе

Смежные источники